In the BioHarmony Drug Report Database
Enasidenib
Idhifa (enasidenib) is a small molecule pharmaceutical. Enasidenib was first approved as Idhifa on 2017-08-01. It is used to treat myeloid leukemia acute in the USA. It is known to target isocitrate dehydrogenase [NADP], mitochondrial. Idhifa’s patents are valid until 2034-09-16 (FDA).
Trade Name
|
Idhifa |
|---|---|
Common Name
|
enasidenib |
ChEMBL ID
|
CHEMBL3989908 |
Indication
|
myeloid leukemia acute |
Drug Class
|
Mutated isocitrate dehydrogenase (IDH) inhibitors |
Image (chem structure or protein)